Medical University of Białystok was created in 1950 in a historic building from the 18th century, Pałac Branickich, which is the most historically important building for the city of Białystok.The university is home to the Medical department with a division of Dentistry and a division of a six-year MD program in English for foreigners, Pharmacology department with Medical Analytics division, and Nursing and Health Protection department with divisions of Physiotherapy, Medical Rescue, Obstetrics, Public Health and Nursing. Wikipedia.
News Article | November 3, 2016
BEVERLY HILLS, CA--(Marketwired - Nov 3, 2016) - Thursday, November 3, 2016) -Announced today, The Central Europe Genomics Center (CEGC) who will provide the 100M Central Europe Market with whole genome sequencing (WGS) technologies, access to other, integrated OMIC technologies, and extended bioinformatics capabilities, as well as a construct a unique Civic Ecosystem to enable the adoption of precision medicine in emerging clinical and consumer markets has been presented a 10 figure plus term sheet under the Senior Advisory of Agent Alan Morell, Creative Management Partners LLC. Said Geoffrey Folkerth, Founder/Managing Partner: "When our associates recommended Alan Morell, (who after months of trying to get their venture renegotiated with a Fortune 50 company unsuccessfully, Alan did it in two phone calls), we vetted and then engaged Alan as Senior Advisor. Alan has brought us to several A-list Pharma Venture groups and we received in short order, a 10 figure plus term sheet thereafter. As I have stated before, Alan's hat is deep with magic!" Said Alan Morell: "Geoffrey and Piotr are International integrity driven respected executives, whose needs were ideal for participation with my financial contacts in Washington DC and beyond, understanding the European Model for Whole Genome Sequencing. Additionally, for the U.S. Audience, to support CEGC initiatives, our Agency is actively exploring a Docudrama for television in connection with the development, production and distribution of a reality television project with a working title Precision Medicine." The CEGC will establish Europe's first and only CLIA certified lab capable of providing a WGS for under $1000, thus enabling population-level national and regional sequencing programs, in a manner analogous to Macrogen (www.macrogen.com), a Korean based private, for-profit company offering sequencing services to Asian clinical and R&D market and Genomics England initiative: http://www.genomicsengland.co.uk, but with more than just sequencing capability in order to add value (e.g., bioinformatics capabilities; complementary assays such as proteomics and molecular and clinical phenotyping). To achieve this, CEGC has obtained exclusivity for Poland for Illumina's XTEN sequencing platform capable of providing an entire genome sequence for under $1000. http://www.illumina.com/systems/hiseq-x-sequencing-system/system.html. The CEGC, in partnership with the Medical University of Bialystok, Poland, will develop integrated infrastructure -- a "Civic Ecosystem" engaging all stakeholders with an interest in clinical medicine and public health to allow personalized medicine products and strategies to be developed, vetted and adopted. To do so the CEGC will, e.g., develop a commercial incubator and engage governmental and regulatory agencies to determine best practices for moving products and practices through the approval processes. This CEGC Civic Ecosystem will also initially leverage a 1,500 patient Community hospital in Poland as a clinical testing ground. CEGC will continue incubate similar projects across the CE region by identifying KOL in genomics and science, creating sequencing projects and assisting in grant applications. CEGC has assembled a team of renowned scientists and life science professionals dedicated to realizing the company's vision and business plan. Key team members include: Dr. Nicholas Schork, Ph.D.: CEO | leading statistical geneticist and applied biomedical researcher; helped set up first two XTEN's at Craig Venter's Human Longevity Institute (HLI) Piotr Staniszewski: Supervisory Board | 15 years C-level experience working with industry and government to build successful Polish business
Kowalewska J.,Medical University of Bialystok
Current Opinion in Organ Transplantation | Year: 2013
Purpose of review: Glomerulonephritis is the leading cause of end-stage renal failure in renal transplant recipients. Recurrence of diseases in kidney allograft provides a unique opportunity to study the mechanisms of kidney disorders leading to the underlying native organ failure. There have been new advances in the understanding of the mechanisms of membranous nephropathy and focal segmental glomerulosclerosis (FSGS). Recent findings: Recent studies of recurrent membranous nephropathy provide evidence of the presence of circulating recipient factor that targets the donor kidney and put forward the evidence of antiphospholipase A2 receptor antibody pathogenicity in some cases, point to a different pathogenesis of recurrent and de-novo membranous nephropathy, and stress the importance of early morphologic recognition of recurrent membranous nephropathy. New advances in understanding the FSGS include identification of soluble podocyte urokinase receptor as a circulating factor leading to the development and recurrence of FSGS after transplantation, imply that podocyte injury may be a reversible lesion, and suggest a dual role of activated parietal epithelial cells in sclerosing glomerular injury as well as in regeneration and repair. Summary: Several new mechanisms of glomerular injury have been implicated in the development of recurrent kidney diseases. When further confirmed, some of these might result in early diagnosis and development of better therapy of the respective disorders. © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins.
Karna E.,Medical University of Bialystok
Molecular and cellular biochemistry | Year: 2012
Products of prolidase [E.C. 22.214.171.124] activity, proline or hydroxyproline, contribute to up-regulation of hypoxia-inducible factor-1α (HIF-1α). Prolidase activity is regulated by β(1)-integrin signaling. We studied the effects of echistatin (a well-known disintegrin) and thrombin (a serine protease capable of activation of integrin α(2)β(1) receptor) on prolidase activity and expressions of prolidase, α(2)β(1)-integrin receptor, focal adhesion kinase (FAK), MAP-kinases (ERK(1) and ERK(2)), and nuclear HIF-1α in human colon adenocarcinoma (DLD-1) cells. It has been found that treatment of the cells with thrombin contributes to decrease in the expression of prolidase and simultaneously increase in its phosphorylation, resulting in maintenance of the enzyme activity. The phenomenon was accompanied by thrombin-dependent recovery of depressed autophosphorylation of FAK (pY(397)) under the effect of FAK inhibitor (1,2,4,5-benzenetetramine tetrahydrochloride). Although integrin α(2)β(1) receptor expression was not affected by thrombin, the signaling induced by thrombin up-regulated nuclear HIF-1α expression. It was accompanied by increase in the expression of MAP kinases, ERK1 and ERK2. It suggests that integrin-dependent signaling through p-FAK is up-regulated in DLD-1 cells and it may represent potential target for anti-cancer therapy.
Glowinska-Olszewska B.,Medical University of Bialystok
European journal of endocrinology / European Federation of Endocrine Societies | Year: 2013
The low number of circulating endothelial progenitor cells (EPCs) has emerged as a biomarker of cardiovascular (CV) risk in adults. Data regarding EPCs in paediatric populations with CV risk factors are limited. The aim of the study was to estimate the EPC number and its relationship with vascular function and structure in children with type 1 diabetes mellitus (T1DM). We performed a comparative analysis of 52 children with T1DM (mean age 14.5 years; diabetes duration, 6.0 years; HbA1c level, 8.5%) and 36 healthy age- and gender-matched control children. EPCs were identified and analysed by flow cytometry with the use of MABs directed against CD34, CD144 (VE-cadherin) and CD309 (VEGFR-2). sICAM-1, hsCRP, thrombomodulin and adiponectin levels were also assessed. We evaluated vascular function (flow-mediated dilation (FMD)) and structure (carotid intima-media thickness (IMT)) ultrasonographically. Frequencies of CD34+ cells were similar in both groups (P=0.30). In contrast, frequencies of CD34+VE-cadherin+ cells were significantly higher in diabetic children compared with the healthy group (P=0.003). Similarly, diabetic patients tended to present with higher frequencies of CD34+VEGFR+ cells (P=0.06). FMD was lower (6.9 vs 10.5%, P=0.002) and IMT was higher (0.50 vs 0.44 mm, P=0.0006) in diabetic children. We demonstrated a significant relationship between CD34+VEGFR-2+ cells and BMI (r=0.3, P=0.014), HDL (r=-0.27, P=0.04), sICAM-1 (r=0.47, P=0.023) and FMD (r=-0.45, P<0.001). Similarly, frequencies of CD34+VE-cadherin+ cells were significantly correlated with BMI (r=0.32, P=0.02) and FMD (r=-0.31, P=0.03). We demonstrated here that increased frequencies of EPCs observed in diabetic children are negatively correlated with endothelial function. Further studies are warranted to assess whether this phenomenon might result from effective mobilisation of EPCs in order to repair damaged endothelium in children at increased risk for atherosclerosis.
Szulc A.,Medical University of Bialystok
Neuroscience letters | Year: 2013
Proton magnetic resonance spectroscopy (1H MRS) enables the evaluation of in vivo brain function. The purpose of the study was to compare 1H MRS measurements in schizophrenic patients, who were clinical responders after short-term antipsychotic treatment, with non-responders and healthy controls. We investigated a group of 47 patients diagnosed with schizophrenia. Patients were examined twice--once after a period of at least 7 days without neuroleptics and the second time at least 4 weeks after therapy with stable doses of medication. The follow-up was available in 42 patients. Baseline MRS measurements of clinical responders were compared with non-responders and the group of healthy controls (N=26). We assessed the following metabolite ratios: NAA (N-acetylaspartate), Glx (complex of GABA, glutamine and glutamate), Cho (choline) and mI (myo-inositol) to creatinine (Cr) in the left frontal and temporal lobes and the thalamus. Responders showed a significantly lower baseline frontal Glx/Cr level than non-responders. Both groups had a significantly lower NAA/Cr ratio in the frontal lobe than the controls, but only non-responders had a significantly lower NAA/Cr ratio in the thalamus. Our results confirm the relationship between the glutamatergic system and pathophysiology of schizophrenia and suggest a significant value of 1H MRS examination in the assessment of the future treatment effect. Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.
Malyszko J.,Medical University of Bialystok
Clinica Chimica Acta | Year: 2010
Endothelium is the largest organ in the body strategically located between the wall of blood vessels and the blood stream. The human body contains approximately 1013 endothelial cells weighing approximately 1kg, and covering a surface area of 4000 to 7000m2 equivalent to the soccer playground. Hypertension and shear stress, inflammation, diabetes-associated factors such as advanced glycated end products, and uremic toxins are some of the prevalent risk factors of endothelial dysfunction in chronic kidney disease. In renal failure endothelial dysfunction and atherosclerosis are almost universal, as well as cardiovascular complications. Endothelial cell damage or injury is invariably associated with such clinical conditions as thrombosis, hypertension, renal failure and atherosclerosis and may be also responsible for accelerated atherosclerosis in patients with chronic renal failure. Traditional risk factor cannot explain the high prevalence and incidence of cardiovascular disease in chronic kidney disease, therefore other non-traditional risk factors such as endothelial dysfunction, oxidative stress or insulin resistance have increasingly been studied. In this review paper mechanism of endothelial dysfunction, including the role of nitric oxide pathway, adipocytokines and hemodialysis-induced endothelial dysfunction is discussed. © 2010 Elsevier B.V.
Malyszko J.,Medical University of Bialystok
Expert Opinion on Emerging Drugs | Year: 2014
Anemia has remained one of the most characteristic and visible manifestations of chronic renal failure for over 150 years. The pathogenesis of anemia of chronic kidney disease (CKD) is multifactorial with inadequate production of erythropoietin being the leading factor. The development of recombinant human erythropoietin (epoetin) in the late 1980s was a milestone in treatment of renal anemia. Despite new drugs, our 'good old friend' erythropoietin-stimulating agents are our everyday life in nephrology practice. It seems that peginesatide would not become a new approach for treating anemia of CKD patients, but rather a falling star. Several new strategies for treating the anemia of CKD are currently being investigated in clinical trials, including prolyl hydroxylase inhibitors and modulators of hepcidin activity, but their role in the management of this condition remains to be established. As shown by the expert in this review, we have to take into account not only the safety and convenience of administration but also cost-effectiveness, while biosimilars are consequently knocking at the doors of dialysis units more and more, particularly in Europe. © Informa UK, Ltd.
Sacha P.,Medical University of Bialystok
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica | Year: 2014
We investigated the genetic similarities and expression of the MexAB-OprM efflux pump system in different clones of multiresistant Pseudomonas aeruginosa strains collected from 2002 to 2009 at two intensive care units (ICU). Regulatory and structural genes mexB, mexR, and mexA were found in 99%, 98%, and 94% of tested strains, respectively. The presence of class 1 integron was found in 90% of the strains, while class 2 integron in only one strain (Psa506). Class 3 integron was not found in any of the tested strains. Among the eleven clones identified, only two clones, I and D, exhibited higher levels of mexB gene expression than the other clones. Clone I had the highest expression (FC = 10.36, p < 0.05). The results of our study indicated a high level of MexAB-OprM pump expression in groups of strains isolated in the years 2008-2009 (FC = 12.92, p < 0.03) and 2002-2006 (FC = 5.14, p < 0.03). There were no statistically significant differences in resistance to all tested antibiotics among the various clones. The high level of antimicrobial resistance may have been due to the coexistence of different resistance mechanisms among the studied P. aeruginosa strains. However, this does not exclude the contribution of the MexAB-OprM pump, particularly in resistance to meropenem and ciprofloxacin. © 2014 APMIS. Published by John Wiley & Sons Ltd.
Malyszko J.,Medical University of Bialystok
Kidney and Blood Pressure Research | Year: 2010
Acute kidney injury (AKI) is diagnosed in 5% of all hospitalized patients and in up to 50% of all ICU patients. In the last years a dramatic rise in the prevalence of AKI has been observed with virtually no change in mortality, reaching up to 50-80% in all dialyzed ICU patients. AKI may progress to end-stage renal disease, and even subclinical episodes of AKI, which are common, may also progress to end-stage renal disease. The early detection of AKI may enable timely intervention and prevention of progression; however, in animal models and in human studies the 'window of therapeutic intervention' is narrow. Different urinary and serum proteins have been intensively investigated as possible biomarkers for the early diagnosis of AKI. There are promising candidate biomarkers with the ability to detect an early and graded increase in tubular epithelial cell injury and distinguish pre-renal disease from acute tubular necrosis. In this review, new emerging biomarkers of AKI are presented and described in some clinical settings, such as cardiac surgery, contrast-induced nephropathy, delayed graft function and ICU/emergency departments, where biomarkers are urgently needed to diagnose, make prognoses and differentiate. Copyright © 2010 S. Karger AG, Basel.
Lukaszewicz-Hussain A.,Medical University of Bialystok
Pesticide Biochemistry and Physiology | Year: 2010
The objective of this paper is to present a short review of the state of knowledge regarding oxidative stress and its role in toxicity of organophosphate insecticides. The information has been obtained by searching the relevant literature using chemical abstracts, PubMed, scopus, medline and other data bases. The significance of the problem has been elucidated. Organophosphate insecticides (OP), apart from inhibition of cholinesterase and presence of cholinergic effects, oxidative stress and hyperglycemia has been reported by many authors as one of the adverse effects in poisoning by OP in both humans and animals. Oxidative stress induced by organophosphate leads to disturbances in the function of different organs and tissues. In subchronic or chronic OP exposition induction of oxidative stress has been reported, by many authors, as the main mechanism of its toxicity. Data were categorized according to animal studies (in vitro and in vivo) and clinical studies. On the basis of relevant literature it is concluded, that determination of oxidative stress parameters can be useful for monitoring people exposed to OP professionally. Supplementation with natural or synthetic antioxidant may be beneficial in OP poisoning, however the rat models of OP poisoning used in those studies do not completely reflect clinical situation. For this reason the clinical trials are needed to explore effectiveness of these antioxidants in protection against toxicity of OP. © 2010 Elsevier Inc.